Biggest Acquisition in Vertex’s History Adds New Endocrinology Business and Two High-Potential Medicines
Vertex Pharmaceuticals has agreed to acquire Crinetics Pharmaceuticals in an all-cash deal valued at approximately $10 billion, marking the largest acquisition in Vertex’s history as the biotechnology company expands beyond its dominant cystic fibrosis franchise into rare endocrine diseases.
$85-Per-Share Cash Offer
Under the agreement:
- Vertex will pay $85 per Crinetics share in cash
- The offer represents roughly a 102% premium to Crinetics’ previous closing price
- The total equity value of the transaction is about $10 billion
- The acquisition is expected to close during the third quarter of 2026, subject to regulatory approvals and shareholder approval.
Following the announcement, Crinetics shares more than doubled in extended trading, while Vertex shares fell modestly as investors assessed the size of the acquisition.
Expansion Beyond Cystic Fibrosis
The acquisition represents a major strategic shift for Vertex, which has built its business around treatments for cystic fibrosis.
With Crinetics, Vertex adds a fifth therapeutic area:
- Cystic fibrosis
- Hematology
- Pain
- Renal disease
- Endocrinology
Vertex CEO Reshma Kewalramani said the acquisition remains consistent with the company’s long-term research and capital allocation strategy and does not signal a broader change in acquisition policy.
Crinetics Brings Two Major Growth Assets
The transaction gives Vertex access to several promising endocrine therapies.
Palsonify
Crinetics markets Palsonify, the first and only once-daily oral treatment approved by the U.S. FDA for adults with acromegaly, a rare disorder caused by excessive growth hormone production.
The medicine has shown encouraging commercial momentum since its launch.
Atumelnant
The acquisition also includes atumelnant, a late-stage experimental therapy for congenital adrenal hyperplasia (CAH), a rare inherited disorder affecting the adrenal glands.
Together, these therapies are projected to generate more than $5 billion in peak annual sales, according to Vertex.
Rare Disease Strategy Continues
Vertex has increasingly sought to diversify beyond cystic fibrosis by expanding into serious diseases with significant unmet medical need.
The company believes its expertise in:
- Rare disease commercialization
- Global regulatory execution
- Specialty medicine distribution
will accelerate growth for Crinetics’ products worldwide.
Pharmaceutical Dealmaking Accelerates
The acquisition is one of the largest pharmaceutical transactions announced in 2026 and reflects a broader rebound in biotechnology mergers and acquisitions.
Industry drivers include:
- Large pharmaceutical companies holding substantial cash reserves
- Attractive biotechnology valuations
- Newly approved innovative medicines
- Growing pressure to replace revenue from upcoming patent expirations.
Financial Outlook
Vertex expects the acquisition to:
- Become accretive to adjusted operating income by 2029
- Strengthen long-term revenue growth
- Diversify earnings beyond cystic fibrosis
- Expand its pipeline of rare disease medicines.
Looking Ahead
The Crinetics acquisition significantly broadens Vertex’s presence in rare diseases while reinforcing its strategy of targeting serious conditions with limited treatment options.
If successfully integrated, the deal could establish endocrinology as Vertex’s next major growth platform alongside its market-leading cystic fibrosis business, while positioning the company for sustained expansion through the remainder of the decade.
